Neurological
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Records whose assigned subject headings cover the central or peripheral nervous system, including the neurodegenerative populations this class has been indexed against. 18 of the 186 records indexed across this publication's scope carry at least one of them, covering 8 of the 17 compounds.
Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.
Record coverage by compound and record class
| Compound | Ph 3 | Ph 2 | Ph 1 | Trial, no phase | Review | Other | All |
|---|---|---|---|---|---|---|---|
| Amylin | 0 | 0 | 0 | 0 | 1 [9] | 3 [16, 17, 18] | 4 |
| Cagrilintide | 0 | 0 | 0 | 0 | 0 | 2 [2, 4] | 2 |
| Dulaglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Eloralintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exenatide | 0 | 0 | 0 | 2 [10, 13] | 0 | 2 [7, 15] | 4 |
| GLP-1 | 0 | 0 | 0 | 0 | 0 | 1 [14] | 1 |
| Liraglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lixisenatide | 0 | 1 [5] | 0 | 0 | 0 | 1 [8] | 2 |
| Maridebart cafraglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mazdutide | 0 | 0 | 0 | 0 | 0 | 1 [3] | 1 |
| Orforglipron | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Petrelintide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pramlintide | 0 | 0 | 0 | 0 | 0 | 3 [6, 11, 12] | 3 |
| Retatrutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Semaglutide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Survodutide | 0 | 0 | 0 | 0 | 0 | 1 [1] | 1 |
| Tirzepatide | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.
A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.
Subject headings that place a record here
The full set is fixed and printed here so the assignment can be checked by hand against the method. 24 of the 24 headings in the set occur on at least one record in scope.
| Subject heading | Records |
|---|---|
| Brain | 6 |
| Neurons | 5 |
| Parkinson Disease | 5 |
| Alzheimer Disease | 3 |
| Amyloid beta-Peptides | 3 |
| Antiparkinson Agents | 3 |
| Hypothalamus | 3 |
| Neuroprotective Agents | 3 |
| Amyloid beta-Protein Precursor | 2 |
| Vagus Nerve | 2 |
| Area Postrema | 1 |
| Cognition | 1 |
| Encephalitis | 1 |
| Hippocampus | 1 |
| Migraine Disorders | 1 |
| Motor Activity | 1 |
| Motor Disorders | 1 |
| Neurodegenerative Diseases | 1 |
| Neurofibrillary Tangles | 1 |
| Neurologic Examination | 1 |
| Paraventricular Hypothalamic Nucleus | 1 |
| Synapsins | 1 |
| Trigeminal Ganglion | 1 |
| tau Proteins | 1 |
The records
18 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.
Phase 2 — 1 record
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 5 | pmid:38598572 | 2024 | Trial of Lixisenatide in Early Parkinson's Disease The New England journal of medicine · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't | human trial | Lixisenatide | Humans; Parkinson Disease; Disease Progression; Peptides; Antiparkinson Agents; Neuroprotective Agents; Treatment Outcome; Injections, Subcutaneous |
Trial, no phase assigned — 2 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 10 | pmid:28781108 | 2017 | Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial Lancet (London, England) · research-article, Randomized Controlled Trial | human trial | Exenatide | Venoms; Humans; Parkinson Disease; Peptides; Neurologic Examination; Treatment Outcome; Drug Administration Schedule; Double-Blind Method |
| 13 | pmid:24662192 | 2014 | Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease Journal of Parkinson's disease · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Exenatide | Venoms; Humans; Parkinson Disease; Peptides; Antiparkinson Agents; Treatment Outcome; Follow-Up Studies; Cognition |
Review or synthesis — 1 record
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 9 | pmid:28269785 | 2017 | The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins Journal of Alzheimer's disease : JAD · Review | other | Amylin | Brain; Animals; Humans; Neurodegenerative Diseases; Diabetes Mellitus, Type 2; tau Proteins; Amyloid beta-Peptides; Islet Amyloid Polypeptide |
Not a registered trial record — 14 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 1 | pmid:41638399 | 2026 | Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation Molecular metabolism · research-article | rodent | Survodutide | Brain; Area Postrema; Hypothalamus; Neurons; Animals; Mice, Inbred C57BL; Humans; Mice |
| 2 | pmid:42260119 | 2026 | A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance Nature metabolism · research-article | rodent | Cagrilintide | Neurons; Vagus Nerve; Animals; Humans; Mice; Rats; Prolactin-Releasing Hormone; Species Specificity |
| 3 | pmid:40479843 | 2025 | Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis EBioMedicine · research-article | rodent | Mazdutide | Brain; Animals; Humans; Mice; Diabetes Mellitus, Type 2; Disease Models, Animal; Peptides; Receptors, Glucagon |
| 4 | pmid:40609154 | 2025 | Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 EBioMedicine · research-article | rodent | Cagrilintide | Brain; Animals; Mice, Knockout; Mice; Obesity; Body Weight; Calcitonin; Receptors, Calcitonin |
| 6 | pmid:33772845 | 2021 | Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients Annals of neurology · Research Support, Non-U.S. Gov't, research-article | human trial | Pramlintide | Trigeminal Ganglion; Animals; Mice, Inbred C57BL; Humans; Mice; Rats; Rats, Sprague-Dawley; Calcitonin Gene-Related Peptide |
| 7 | pmid:30640362 | 2019 | Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial JAMA neurology · Research Support, Non-U.S. Gov't, research-article | human trial | Exenatide | Brain; Neurons; Humans; Parkinson Disease; Insulin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Signal Transduction |
| 8 | pmid:29175324 | 2018 | Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease Biochemical and biophysical research communications · Research Support, Non-U.S. Gov't | rodent | Lixisenatide | Neurofibrillary Tangles; Animals; Mice, Inbred C57BL; Mice, Transgenic; Mice; Encephalitis; Alzheimer Disease; Peptides |
| 11 | pmid:24169554 | 2014 | Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors Endocrinology · Research Support, Non-U.S. Gov't | rodent | Pramlintide | COS Cells; Animals; Humans; Rats; Calcitonin; Peptide Fragments; Receptors, Calcitonin; Hypoglycemic Agents |
| 12 | pmid:24239383 | 2014 | Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition Neurobiology of aging · Research Support, Non-U.S. Gov't | rodent | Pramlintide | Hippocampus; Neurons; Cells, Cultured; Animals; Humans; Mice; Alzheimer Disease; Disease Models, Animal |
| 14 | pmid:25202980 | 2014 | The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | rodent | GLP-1 | Hypothalamus; Paraventricular Hypothalamic Nucleus; Neurons; Vagus Nerve; Animals; Mice, Transgenic; Mice; Rats |
| 15 | pmid:23728174 | 2013 | Exenatide and the treatment of patients with Parkinson's disease The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | human trial | Exenatide | Venoms; Humans; Parkinson Disease; Disease Progression; Weight Loss; Constipation; Peptides; Antiparkinson Agents |
| 16 | pmid:23794448 | 2013 | Amylin deposition in the brain: A second amyloid in Alzheimer disease? Annals of neurology · Research Support, Non-U.S. Gov't, research-article | other | Amylin | Brain; Humans; Alzheimer Disease; Diabetic Angiopathies; RNA, Messenger; Aged; Aged, 80 and over; Female |
| 17 | pmid:20707388 | 2010 | The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry · Comparative Study, Research Support, Non-U.S. Gov't | rodent | Amylin | Animals; Rats; Diabetes Mellitus, Type 2; Phenols; Thiazoles; Catechin; Flavonoids; Amyloid |
| 18 | pmid:18458326 | 2008 | Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proceedings of the National Academy of Sciences of the United States of America · research-article | rodent | Amylin | Hypothalamus; Adipose Tissue; Animals; Rats; Obesity; Disease Models, Animal; Body Weight; Amyloid |
What this page does not say
- It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
- It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
- It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
- It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.